BRPI0410466A - derivados de indol como inibidores de fator xa - Google Patents

derivados de indol como inibidores de fator xa

Info

Publication number
BRPI0410466A
BRPI0410466A BRPI0410466-8A BRPI0410466A BRPI0410466A BR PI0410466 A BRPI0410466 A BR PI0410466A BR PI0410466 A BRPI0410466 A BR PI0410466A BR PI0410466 A BRPI0410466 A BR PI0410466A
Authority
BR
Brazil
Prior art keywords
factor
compounds
formula
factor viia
inhibitors
Prior art date
Application number
BRPI0410466-8A
Other languages
English (en)
Inventor
Marc Nazare
Volkmar Wehner
Kurt Ritter
Volker Laux
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of BRPI0410466A publication Critical patent/BRPI0410466A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)

Abstract

"DERIVADOS DE INDOL COMO INIBIDORES DE FATOR Xa". A presente invenção se refere a compostos da fórmula I na qual R¬ 0¬; R¬ 1¬ ; R¬ 2¬; R¬ 3¬; R¬ 4¬; R¬ 5¬; R¬ 6¬; R¬ 7¬; Q; V, G e M têm os significados indicados nas reivindicações. Os compostos das fórmulas I são compostos farmacologicamente ativos valiosos. Eles exibem um forte efeito anti-trombótico e são adequados, por exemplo, para a terapia e profilaxia de distúrbios cardiovasculares como doenças tromboembólicas ou restenoses. Eles são inibidores reversíveis do fator Xa (FXa) e/ou fator VIIa (FVIIa) de enzimas de coagulação sangüínea, e podem em geral ser aplicados em condições nas quais uma atividade indesejada de fator Xa e/ou fator Vila está presente ou para a cura ou prevenção da qual uma inibição de fator Xa e/ou fator VIIa é pretendida. A invenção também refere-se a processos para a preparação de compostos da fórmula I, seu uso, em particular como ingredientes ativos em produtos farmacêuticos, e preparações farmacêuticas compreendendo-os.
BRPI0410466-8A 2003-05-19 2004-05-05 derivados de indol como inibidores de fator xa BRPI0410466A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03011306A EP1479677A1 (en) 2003-05-19 2003-05-19 New indole derivatives as factor xa inhibitors
PCT/EP2004/004751 WO2004101554A1 (en) 2003-05-19 2004-05-05 New indole derivatives as factor xa inhibitors

Publications (1)

Publication Number Publication Date
BRPI0410466A true BRPI0410466A (pt) 2006-05-30

Family

ID=33040953

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410466-8A BRPI0410466A (pt) 2003-05-19 2004-05-05 derivados de indol como inibidores de fator xa

Country Status (15)

Country Link
US (1) US7196103B2 (pt)
EP (2) EP1479677A1 (pt)
JP (1) JP4676960B2 (pt)
AT (1) ATE475659T1 (pt)
AU (1) AU2004238495B2 (pt)
BR (1) BRPI0410466A (pt)
CA (1) CA2526066A1 (pt)
CL (1) CL2004001074A1 (pt)
DE (1) DE602004028367D1 (pt)
MX (1) MXPA05012232A (pt)
PA (1) PA8603601A1 (pt)
PE (1) PE20050156A1 (pt)
TW (1) TW200510393A (pt)
UY (1) UY28325A1 (pt)
WO (1) WO2004101554A1 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1314733A1 (en) * 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
US7358268B2 (en) * 2002-12-04 2008-04-15 Sanofi-Aventis Deutschland Gmbh Imidazole derivatives as factor Xa inhibitors
US7429581B2 (en) 2002-12-23 2008-09-30 Sanofi-Aventis Deutschland Gmbh Pyrazole-derivatives as factor Xa inhibitors
EP1479675A1 (en) * 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Indazole-derivatives as factor Xa inhibitors
EP1479677A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH New indole derivatives as factor xa inhibitors
US7741341B2 (en) 2003-05-19 2010-06-22 Sanofi-Aventis Deutschland Gmbh Benzimidazole-derivatives as factor Xa inhibitors
US7223780B2 (en) * 2003-05-19 2007-05-29 Sanofi-Aventis Deutschland Gmbh Triazole-derivatives as blood clotting enzyme factor Xa inhibitors
US7317027B2 (en) * 2003-05-19 2008-01-08 Sanofi-Aventis Deutschland Gmbh Azaindole-derivatives as factor Xa inhibitors
EP1571154A1 (en) * 2004-03-03 2005-09-07 Aventis Pharma Deutschland GmbH Beta-aminoacid-derivatives as factor Xa inhibitors
FR2888847B1 (fr) 2005-07-22 2007-08-31 Sanofi Aventis Sa Derives de n-(heteriaryl)-1-heteorarylalkyl-1h-indole-2- carboxamides, leur preparation et application en therapeutique
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
PT3095447T (pt) 2006-02-03 2022-01-24 Opko Renal Llc Tratamento da insuficiência e deficiência de vitamina d com 25-hidroxivitamina d2 e 25-hidroxivitamina d3
DK2037936T3 (da) 2006-06-21 2014-09-22 Opko Renal Llc Fremgangsmåde til behandling og forebyggelse af sekundær hyperparathyroidisme
KR101691876B1 (ko) 2007-04-25 2017-01-02 사이토크로마 인코포레이티드 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
ES3047207T3 (en) 2007-04-25 2025-12-03 Opko Renal Llc Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
TW200920369A (en) 2007-10-26 2009-05-16 Amira Pharmaceuticals Inc 5-lipoxygenase activating protein (flap) inhibitor
CA2727055C (en) 2008-01-11 2016-12-20 Albany Molecular Research, Inc. (1-azinone) -substituted pyridoindoles as mch antagonists
ES2593356T3 (es) 2008-04-02 2016-12-07 Opko Ireland Global Holdings, Ltd. Métodos, composiciones, usos y kits útiles para la deficiencia de la vitamina D y trastornos relacionados
JP5791500B2 (ja) 2008-05-23 2015-10-07 パンミラ ファーマシューティカルズ，エルエルシー． ５−リポキシゲナーゼ活性化タンパク質阻害剤
US8546431B2 (en) 2008-10-01 2013-10-01 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
CN107233337A (zh) 2009-04-29 2017-10-10 阿马里纳药物爱尔兰有限公司 含有epa和心血管剂的药物组合物以及使用其的方法
WO2011003012A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof
US8629158B2 (en) * 2009-07-01 2014-01-14 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
WO2011003005A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine mch-1 antagonists, methods of making, and use thereof
WO2011003021A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
US11672809B2 (en) 2010-03-29 2023-06-13 Eirgen Pharma Ltd. Methods and compositions for reducing parathyroid levels
US8697700B2 (en) 2010-12-21 2014-04-15 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline MCH-1 antagonists, methods of making, and uses thereof
WO2012088124A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Tetrahydro-azacarboline mch-1 antagonists, methods of making, and uses thereof
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
KR20180123100A (ko) 2016-03-28 2018-11-14 옵코 아일랜드 글로벌 홀딩스 리미티드 비타민 d 치료 방법

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11469A (en) * 1854-08-08 boynton
US4675332A (en) * 1984-12-10 1987-06-23 Warner-Lambert Company Acidic tetrazolyl substituted indole compounds and their use as antiallergy agents
JPH0287282A (ja) * 1988-09-22 1990-03-28 Nec Corp グラフ作図レイアウト決定方式
US5506134A (en) 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
US5788965A (en) 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
TW229140B (pt) * 1992-06-05 1994-09-01 Shell Internat Res Schappej B V
ZA953361B (en) 1994-04-26 1996-01-12 Selectide Corp Factor Xa inhibitors
FR2763337B1 (fr) * 1997-05-13 1999-08-20 Sanofi Sa Nouveaux derives du triazole, un procede pour leur preparation et compositions pharmaceutiques les contenant
US20040043995A1 (en) 1997-05-13 2004-03-04 Eric Bignon Novel triazole derivatives, process for their preparation and pharmaceutical compositions containing them
BR9814340B1 (pt) * 1997-12-24 2010-07-13 compostos derivados de indol, processo para a preparação dos mesmo e composição farmacêutica.
JP2002522386A (ja) * 1998-08-03 2002-07-23 イーライ・リリー・アンド・カンパニー インドールｓＰＬＡ２インヒビター
EP0987274A1 (en) 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Factor VIIa Inhibitors
US6486211B1 (en) * 1999-10-22 2002-11-26 Smithkline Beecham Corporation Indole compounds
US7053070B2 (en) * 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
US6436965B1 (en) * 2000-03-02 2002-08-20 Merck Frosst Canada & Co. PDE IV inhibiting amides, compositions and methods of treatment
IL152979A0 (en) * 2000-05-26 2003-06-24 Nippon Shinyaku Co Ltd Heterocyclic compounds
BR0111230A (pt) * 2000-05-31 2003-06-10 Astrazeneca Ab Composto, e, uso e processo para a preparação do mesmo
US20030165837A1 (en) 2000-06-14 2003-09-04 The Scripps Research Institute Method for screening DNA binding
WO2001096313A1 (en) * 2000-06-14 2001-12-20 The Scripps Research Institute Distamycin a analogs
US6525202B2 (en) * 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
DE10147672A1 (de) * 2001-09-27 2003-04-10 Bayer Ag Substituierte 2,5-Diamidoindole und ihre Verwendung
US7064135B2 (en) * 2001-10-12 2006-06-20 Novo Nordisk Inc. Substituted piperidines
EP1314733A1 (en) 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
US7358268B2 (en) 2002-12-04 2008-04-15 Sanofi-Aventis Deutschland Gmbh Imidazole derivatives as factor Xa inhibitors
US7429581B2 (en) 2002-12-23 2008-09-30 Sanofi-Aventis Deutschland Gmbh Pyrazole-derivatives as factor Xa inhibitors
US7078419B2 (en) * 2003-03-10 2006-07-18 Boehringer Ingelheim Pharmaceuticals, Inc. Cytokine inhibitors
US7049323B2 (en) * 2003-04-25 2006-05-23 Bristol-Myers Squibb Company Amidoheterocycles as modulators of the melanocortin-4 receptor
EP1479675A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Indazole-derivatives as factor Xa inhibitors
EP1479677A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH New indole derivatives as factor xa inhibitors
US7223780B2 (en) 2003-05-19 2007-05-29 Sanofi-Aventis Deutschland Gmbh Triazole-derivatives as blood clotting enzyme factor Xa inhibitors
US7741341B2 (en) 2003-05-19 2010-06-22 Sanofi-Aventis Deutschland Gmbh Benzimidazole-derivatives as factor Xa inhibitors
US7405670B2 (en) * 2005-07-29 2008-07-29 Fitzgerald Timothy W Method and system for detecting and isolating stray voltage

Also Published As

Publication number Publication date
US7196103B2 (en) 2007-03-27
US20050033049A1 (en) 2005-02-10
CA2526066A1 (en) 2004-11-25
EP1633746A1 (en) 2006-03-15
JP4676960B2 (ja) 2011-04-27
AU2004238495B2 (en) 2010-07-22
ATE475659T1 (de) 2010-08-15
PA8603601A1 (es) 2004-11-26
EP1479677A1 (en) 2004-11-24
TW200510393A (en) 2005-03-16
WO2004101554A1 (en) 2004-11-25
CL2004001074A1 (es) 2005-03-28
UY28325A1 (es) 2004-12-31
DE602004028367D1 (de) 2010-09-09
EP1633746B1 (en) 2010-07-28
AU2004238495A1 (en) 2004-11-25
JP2006528940A (ja) 2006-12-28
MXPA05012232A (es) 2006-08-18
PE20050156A1 (es) 2005-04-27

Similar Documents

Publication Publication Date Title
PE20050156A1 (es) DERIVADOS DE INDOL COMO INHIBIDORES DEL FACTOR Xa
BRPI0410430A (pt) derivados de indazol como inibidores de fato xa
PT1349847E (pt) Novos derivados de oxibenzamidas como inibidores do factor xa
MXPA04004797A (es) Indol-2-carboxamidas como inhibidores del factor xa.
TW200505914A (en) Pyrazole-derivatives as factor Xa inhibitors
BRPI0508048A (pt) derivados de pirrol como inibidores do fator xa
DK1423357T3 (da) Urinstofderivater med antiproteolytisk aktivitet
YU29702A (sh) N-gvanidinoalkilamidi, njihovo dobijanje, njihova primena i farmaceutski preparati koji ih obuhvataju
BRPI0410763A (pt) derivados de triazol como inibidores de fator xa
TW200504027A (en) Imidazole-derivatives as factor Xa inhibitors
TW200503696A (en) Benzimidazole-derivatives as factor Xa inhibitors
TNSN05296A1 (en) AZAINDOLE-DERIVATIVES AS FACTOR Xa INHIBITORS
TW200716620A (en) Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide-derivatives as factor Xa inhibitors
JO2467B1 (en) New indole derivatives as an inhibitor of Xa
DE60321700D1 (de) Pyrazolderivate und deren verwendung als therapeutische mittel für durch hiv vermittelte krankheiten

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 8A, 9A E 10A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2258 DE 15/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 8A, 9A, 10A, 11A, 12A, 13A, 14A, 15A E 16A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.